148 related articles for article (PubMed ID: 17348833)
61. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
62. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities.
Schroeder EK; Basso LA; Santos DS; de Souza ON
Biophys J; 2005 Aug; 89(2):876-84. PubMed ID: 15908576
[TBL] [Abstract][Full Text] [Related]
63. Synthesis and antitubercular activity of heterocycle substituted diphenyl ether derivatives.
Kini SG; Bhat A; Pan Z; Dayan FE
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):730-6. PubMed ID: 20443682
[TBL] [Abstract][Full Text] [Related]
64. Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach.
Chollet A; Mourey L; Lherbet C; Delbot A; Julien S; Baltas M; Bernadou J; Pratviel G; Maveyraud L; Bernardes-Génisson V
J Struct Biol; 2015 Jun; 190(3):328-37. PubMed ID: 25891098
[TBL] [Abstract][Full Text] [Related]
65. Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
Sharma SK; Parasuraman P; Kumar G; Surolia N; Surolia A
J Med Chem; 2007 Feb; 50(4):765-75. PubMed ID: 17263522
[TBL] [Abstract][Full Text] [Related]
66. Structural Basis for Cyclopropanation by a Unique Enoyl-Acyl Carrier Protein Reductase.
Khare D; Hale WA; Tripathi A; Gu L; Sherman DH; Gerwick WH; Håkansson K; Smith JL
Structure; 2015 Dec; 23(12):2213-2223. PubMed ID: 26526850
[TBL] [Abstract][Full Text] [Related]
67. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum.
Surolia N; Surolia A
Nat Med; 2001 Feb; 7(2):167-73. PubMed ID: 11175846
[TBL] [Abstract][Full Text] [Related]
68. Design, synthesis, structural characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-ray diffraction and evaluation of a new class of phenylaminoacetic acid benzylidene hydrazines as pfENR inhibitors.
Samal RP; Khedkar VM; Pissurlenkar RR; Bwalya AG; Tasdemir D; Joshi RA; Rajamohanan PR; Puranik VG; Coutinho EC
Chem Biol Drug Des; 2013 Jun; 81(6):715-29. PubMed ID: 23398677
[TBL] [Abstract][Full Text] [Related]
69. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
[TBL] [Abstract][Full Text] [Related]
70. Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.
Izumizono Y; Arevalo S; Koseki Y; Kuroki M; Aoki S
Eur J Med Chem; 2011 May; 46(5):1849-56. PubMed ID: 21397998
[TBL] [Abstract][Full Text] [Related]
71. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
[TBL] [Abstract][Full Text] [Related]
72. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
Lone MY; Athar M; Gupta VK; Jha PC
J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
[TBL] [Abstract][Full Text] [Related]
73. Triclosan and its derivatives as antimycobacterial active agents.
Vosátka R; Krátký M; Vinšová J
Eur J Pharm Sci; 2018 Mar; 114():318-331. PubMed ID: 29277667
[TBL] [Abstract][Full Text] [Related]
74. In silico evaluation and in vitro growth inhibition of Plasmodium falciparum by natural amides and synthetic analogs.
da Silva MA; Veloso MP; de Souza Reis K; de Matos Passarini G; Dos Santos APA; do Nascimento Martinez L; Fokoue HH; Kato MJ; Teles CBG; Kuehn CC
Parasitol Res; 2020 Jun; 119(6):1879-1887. PubMed ID: 32382989
[TBL] [Abstract][Full Text] [Related]
75. Inhibiting activities of the secondary metabolites of Phlomis brunneogaleata against parasitic protozoa and plasmodial enoyl-ACP Reductase, a crucial enzyme in fatty acid biosynthesis.
Kirmizibekmez H; Calis I; Perozzo R; Brun R; Dönmez AA; Linden A; Rüedi P; Tasdemir D
Planta Med; 2004 Aug; 70(8):711-7. PubMed ID: 15326547
[TBL] [Abstract][Full Text] [Related]
76. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase.
Levy CW; Baldock C; Wallace AJ; Sedelnikova S; Viner RC; Clough JM; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
J Mol Biol; 2001 May; 309(1):171-80. PubMed ID: 11491286
[TBL] [Abstract][Full Text] [Related]
77. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
Shah P; Siddiqi MI
SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
[TBL] [Abstract][Full Text] [Related]
78. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.
Argyrou A; Vetting MW; Blanchard JS
J Am Chem Soc; 2007 Aug; 129(31):9582-3. PubMed ID: 17636923
[No Abstract] [Full Text] [Related]
79. Dynamics of Plasmodium falciparum enoyl-ACP reductase and implications on drug discovery.
Lindert S; McCammon JA
Protein Sci; 2012 Nov; 21(11):1734-45. PubMed ID: 22969045
[TBL] [Abstract][Full Text] [Related]
80. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.
Pan P; Tonge PJ
Curr Top Med Chem; 2012; 12(7):672-93. PubMed ID: 22283812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
